30 Mar – 5 Apr 2026

Methodology: This weekly brief synthesises the source coverage listed below and adds editorial framing for Australian health operators. It is not medical advice and should be read alongside the original reporting.

Faz Australia’s MedTalk AI pilot embedding an AI scribe into Epic via HL7 has made AI scribe integration a binary strategic choice for every Australian EMR vendor.

AI moving from experiment to routine care was the clearest force this week. Faz’s ACT pilot and MedLuma’s Best Practice embed show purchasers now prize HL7 connectivity, local clinical governance and citation trails as much as model accuracy. Vendors that can ship HL7-ready scribe components, audit logs and source‑locked guidance will win public and large GP network contracts. Clinicians and health services face a budgeting decision: buy integration and training now or accept slower workflows and rising administrative load.

Public digital scale and procurement tension rose in Canberra and at the national level. ACT’s MyDHR now covers 271,000 accounts and avoided tens of thousands of repeat blood draws, while the Medicare Mental Health Check-In LiCBT program launches with $588.5 million over eight years. Those moves shift procurement priorities toward platforms that can handle high transaction volumes, identity verification and consent management. Health IT suppliers without robust privacy, identity and cloud scale will be squeezed out of major government work.

Drug funding and prescribing reforms are forcing integration work into clinical software roadmaps. PBS added three new indications for pembrolizumab from 1 April, the TGA gave provisional approval for Wegovy to treat MASH with F2–F3 fibrosis, and PBAC recommended a tightly managed PBS pathway for GLP-1 weight drugs focused on BMI over 35 with cardiovascular disease. The combined effect is immediate: hospitals and GP software must update formularies, embed eligibility checks and capture outcomes data if they are to manage budget exposure and meet audit expectations.

Contrarian read. Momentum on AI and genomics risks creating a two‑tier system unless infrastructure and workforce investment keep pace. New Zealand’s Illumina onshore sequencing pilot will process 6,000 samples and shows how local capacity short‑circuits offshore dependency. Australia has not yet matched that financing or governance clarity. Without targeted funding for lab networks, data governance and clinician upskilling, urban private clinics will capture most benefits while rural and public services lag.

Faz Australia won the ACT Health MedTalk AI pilot to trial an AI scribe inside Epic - forces EMR vendors to prioritise HL7-ready AI integrations or lose access to large public hospitals.
MedLuma secured embedding in Best Practice - gives tools that lock in Australian guidelines and CPD citations a measurable market advantage over global platforms.
ACT Digital Health Record reached 271,000 MyDHR accounts and consolidated over 50 legacy systems - creates procurement demand for scalable integration, consent management and privacy tooling from vendors bidding for public contracts.
PBS expanded pembrolizumab indications from 1 April - requires hospitals to update formularies and reallocate oncology budgets to cover higher drug spend immediately.
TGA granted provisional approval for Wegovy to treat metabolic dysfunction associated steatohepatitis F2–F3 - enables GP prescribing ahead of PBS listing and forces primary care IT to add prescribing workflows and monitoring templates.
Medicare launched the Mental Health Check-In LiCBT program with $588.5 million over eight years - pushes general practice systems to integrate triage, referral and digital mental health data flows.
PBAC recommended a cautious PBS rollout for GLP-1 obesity drugs prioritising BMI>35 with cardiovascular disease - narrows the initial eligible population and requires eligibility verification logic in prescribing systems.
Victoria progressed independent pharmacy prescribing reforms - compels pharmacy and GP software to exchange prescribing records and maintain auditable decision support to meet safety requirements.
Illumina’s New Zealand onshore sequencing pilot will process more than 6,000 samples over two years - raises the bar for Australia to invest in domestic genomics capacity or risk losing diagnostic and research work offshore.